What’s next for the Avacta share price?

The Avacta share price has crashed by almost 80%! But is this a buying opportunity for patient investors? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

It’s been a rough 12 months for the Avacta (LSE:AVCT) share price. Despite the diagnostics business making solid progress, the stock has dropped by almost 80%! Often these situations can present excellent buying opportunities for my portfolio. But is this a trap? Let’s explore what might happen next to Avacta and its share price

A future leader in the fight against cancer?

I’ve explored this business before. But as a quick reminder, Avacta is a medical diagnostics business primarily focused on developing cancer therapies.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

In 2020, Avacta’s share price exploded as management leveraged its knowledge and expertise to develop rapid testing kits in the fight against Covid-19. This initial level of excitement from shareholders has since waned. And this is undoubtedly a contributing factor to the stock’s recent downward trajectory.

But in the meantime, some significant milestones have been hit. In mid-2021, Phase 1 clinical trials for its targeted chemotherapy treatment began. And last month, the company reported positive initial results with no safety concerns. As such, the drug dosage is being increased, moving Avacta closer to the next stage of clinical trials.

But what makes this drug so special? Without going too scientific, chemotherapy is effectively a poison that kills cancer cells. The problem is that it also has a habit of killing healthy cells. That’s why the treatment can have such unpleasant side effects.

Avacta’s drug has been designed to only attack cells that contain a specific concentration of a protein found only in solid tumours. In other words, if it works, the risk of collateral damage to healthy cells is almost entirely eliminated.

Given that the generic chemotherapy market is expected to reach $1.38bn by 2024, that presents an enormous opportunity for the Avacta share price.

The risks surrounding the Avacta share price

As exciting as a new and improved chemotherapy treatment is, there remains a long road ahead. On average, only 9% of Phase 1 drugs ever reach the market. Even if Avacta can beat the overwhelming odds, there still remains the issue of funding.

Running clinical trials is not cheap. And as it stands, the group only has around £37m of cash on its balance sheet. That may seem like a lot until considering the average cost of drug development is about £760m. In other words, the firm will have to raise capital to see this project to the end.

Typically, young biotechs get a sponsorship from a larger pharmaceutical giant after proving their drug has potential. Usually, this takes place around Phase 2 trials. And I wouldn’t be surprised if that’s what happens with this business.

But in the meantime, the company has to raise capital by itself. And with the Avacta share price dropping so rapidly, its equity-raising capabilities are pretty limited compared to a few months ago.

Time to buy?

Avacta is by no means a one-trick pony. But a lot of resources are being poured into its chemotherapy treatment, which could turn out to be a dud. Consequently, the future of the Avacta share price seems uncertain. Personally, I’m not interested in adding this level of risk to my portfolio. So I’ll be keeping this stock on my watchlist for now.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Social media and digital online concept, woman using smartphone
Investing Articles

Will Lloyds shares recover in 2022?

Lloyds shares have struggled this year and the looming recession won't help. But I'd still buy them today.

Read more »

Two hands holding champagne glasses toasting each other with Paris in the background
Investing Articles

Can the stock market make me rich even now?

Here are three ways I'm coping with the stock market's recent bout of weakness and aiming to build wealth in…

Read more »

Cogs turning against each other
Investing Articles

3 top investment trusts to buy right now

Investment trusts offer a wide range of options for investors. And in troubled times, they provide some safety through diversification…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Why hasn’t the FTSE 100 crashed in 2022?

The catastrophic events of 2022 have left investors around the globe fearing the worst for stock markets. And some have…

Read more »

Trader on video call from his home office
Investing Articles

2 inflation-resistant FTSE 100 stocks to buy today

Soaring inflation could dent my returns if I don't take care. Here are two top inflation-resistant FTSE 100 stocks I'd…

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

Why a bear market is an investor’s best friend

A bear market can certainly be scary. But any investor tempted to sell might benefit by looking at Warren Buffett's…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The Rolls-Royce share price could be stuck below £1 for a while. Should I buy?

The Rolls-Royce share price has been trading at penny stock levels since April. Could the stock be a bargain at…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

I’m aiming to make £45,000 in passive income with UK shares and never work again!

Investing regularly in UK shares can generate a substantial passive income over the long run. Zaven Boyrazian demonstrates how.

Read more »